Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers.

Trial Profile

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Becaplermin (Primary) ; Plerixafor (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 25 Apr 2013 Planned End Date changed from 1 Dec 2012 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 25 Apr 2013 Planned initiation date changed from 1 Jan 2012 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top